TNBC: Adding capecitabine boosts disease-free survival in prospective trial
SAN ANTONIO – In a phase 3 trial of 585 women with triple-negative breast cancer, 5-year disease free survival was 86.26% in the capecitabine group, compared with 80.23% in the control group.